Translate page

iCMLf

Alliance

    CML publications

    Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

    Clinical papers

    Scientific papers

    More CML Publications 2023

    Clinical Publications Scientific Publications
    February 2024
    Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANS1::ARC1A) alteration: A case report with insights on the molecular landscape
    Fontana D et al. Ann Hematol, February 2024 (epub ahead of print)
    Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia
    Jiang L et al. Genomics, February 2024
    (epub ahead of print)
    – open access publication
    Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia
    Wang L et al. Int J Lab Hematol, February 2024 (epub ahead of print)
    Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models
    Ansari AS et al. J Control Release, February 2024 (epub ahead of print)
    Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction
    Mu H et al. Hematol Transfus Cell Ther, February 2024
    (epub ahead of print)
    – open access publication
    AS1041, a novel derivative of marine natural compound Aspergiolide A induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation
    Lu X et al. Biomed Pharmacother, February 2024 – open access publication
    HIF2-alpha expression in CML patients receiving hydroxyurea prior to imatinib that achieved major molecular response (MMR) versus in those not achieving MMR
    Rinaldi I et al. J Blood Med, February 2024
    (epub ahead of print)
    – open access publication

    Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib
    Klaihmon P et al. Sci Rep, February 2024 (epub ahead of print)

     
      The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia - Review
    El-Tanani M et al. Pathol Res Pract, February 2024 – open access publication
    January 2024
    Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A Case report and literature review
    Li Y et al. Medicine (Baltimore), January 2024 – open access publication
    Circ-SIRT1 upregulated ATG12 to facilitate imatinib resistance in CML through interacting with EIF4A3
    Zhang R et al. Gene, January 2024
    Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: A Comparative study from the Chronic Malignancies Working Party of the EBMT (CHWP-EBMT)
    Ortí G et al. Transplant Cell Ther, January 2024 – open access publication
    Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia – Review
    Sun J et al. Int J Biol Sci, January 2024
    – open access publication
    Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors
    Velmaat L and Cortes J. Blood, January 2024 (epub ahead of print) 
    Role of miRNAs to control the progression of chronic myeloid leukemia by their expression levels
    Bansal M et al. Med Oncol, January 2024
    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Jabbour E et al. Leukemia, January 2024
    (epub ahead of print)
    – open access publication 
    Extracellular vesicles in the chronic myeloid leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules - Review
    Bernardi S et al. Front Oncol, January 2024 – open access publication
    Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches
    Lipton JH. Clin Drug Investig, January 2024
    (epub ahead of print) 
    Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation
    Boucher L et al. Leuk Res, January 2024 (epub ahead of print)
    How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to J.P Gale and J. Chen
    Pfirrmann M et al. Leukemia, January 2024
    (epub ahead of print)
    – open access publication 
    Identification and validation of hub genes and molecular classifications associated with chronic myeloid leukemia
    Zhong F et al. Front Oncol, January 2024
    – open access publication
    Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with Dasatinib – Interim results from the DAstop2 trial
    Flygt H et al. Leukemia, January 2024 (epub ahead of publication)
    – open access publication 
    Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSC) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
    Benjamin ESB Cell Signal, January 2024 (epub ahead of print)
    Safety and efficacy of asciminib in a chronic myloid leukemia patient with chronic kidney disease: A case report
    Alshurufa A et al. Case Rep Oncol, January 2024
    – open access publication 
    Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia
    Lettnin AP et al. Gene, January 2024
    A review of the therapeutic role of bosutinib in chronic myeloid leukemia – Review
    Kantarjian HM et al. Clin Lymphoma Myeloma Leuk, January 2024
    Activating p53 abolishes self-renewal of quiescent leukemic stem cells in residual CML disease
    Scott MT et al. Nat Commun, January 2024
    – open access publication
     
    Safety and efficacy of tyrosine kinase inhibitors in very elderly patients (≥ 75 years) with chronic myeloid leukemia
    Costa A et al. J Clin Med, January 2024
    open access publication
    Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
    Imeri J et al. Front Immunol, January 2024
    – open access publication 
    Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript
    Dereme J et al. Ann Hematol, January 2024 (epub ahead of print)
     
    What do atomic bomb survivors teach us about treatment-free remission in people with chronic myeloid leukemia
    Radivoyevitch T et al. Leukemia, January 2024
    – open access publication
     
    How to individualized therapy after failing milestones in chronic myeloid leukemia: weighting late response and early death from CML against risk of alternative therapy
    Hehlmann R and Lauseker M. Leukemia, January 2024 (epub ahead of print)
    – open access publication
     
    Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL fusion gene in Ph-positive leukemias
    Sponseiler I et al. Am J Hematol, January 2024 – open access publication
     
    December 2023
    CML and the WHO: Why?
    Berman E et al. J Clin Oncol, December 2023 (epub ahead of print)
    Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications
    Ouyaung D et al. Cancers(Basel), December 2023
    – open access publication
    Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML
    Winn AN et al. JAMA Netw Open, December 2023
    open access publication
     
    Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis
    Wu A et al. Leukemia, December 2023
    Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group
    Rivera D et al. Mod Pathol, December 2023
    (epub ahead of print)
    – open access publication
    The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
    Machova Polakova K et al. Leukemia, December 2023 (epub ahed of print) – open access publication
    Accelerated-phase CML: de novo and transformed
    Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023
    – open access publication 
     

    A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
    Zenebe B et al. Hematology Review, December 2023
    – open access publication

    Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review
    Atallah E et al. Ther Adv Hematol, December 2023
    open access publication
    C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells
    Zehtabcheh S et al. Mol Biol Rep, December 2023

    Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French
    Réa D et al. Bull Cancer, December 2023
    (epub ahead of print)
    – open access publication 

    The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia
    Liu XY et al. Hematology, December 2023
    – open access publication
     
    Resistance mutations in CML and how we approach them - Review
    Soverini S et al. Hematology Am Soc Educ Program, December 2023
    – open access publication
    Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia
    Yin L et al. Hematology, December 2023
    – open access publication
    SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review
    Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023 (epub ahead of print) 
    miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1
    Zhang X et al. Cell Mol Life Sci, December 2023 - open access publication
    How to improve treatment-remission eligibility in CML? Review
    Costa A and Breccia M. Br J Haematol, December 2023 (epub ahead of print) – open access publication 
    Osimertinib covalently binds to CD34 and eliminates progenitor cells
    Xia L et al. Cancer Res, December 2023
    (epub ahead of print)
    The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
    Liu L et al. Hematology, December 2023
    – open access publication 
    Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells
    Yang Y et al. Hematology, December 2023
    – open access publication
    Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019
    Sasaki K et al. Cancer, December 2023
     
    Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan
    Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023
     
    Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans
    Hofmann J et al. Leukemia, December 2023 – open access publication
     
    Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
    Kongruang A et al. Hematology, December 2023
    – open access publication
     
    An update of the management of advanced phase chronic myeloid leukemia – Review
    Short NJ et al. Curr Hematol Malig Rep, December 2023
     
    Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic
    Collins JB et al. J Oncol Pharm Pract, December 2023
    (epub ahead of print)
    – open access publication
     
    Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review
    Iurlo A et al. Curr Treat Options Oncol, December 2023 (epub ahead of print)
     
    Exploration of treatment-free remission in CML, based on molecular monitoring – Review
    Zhang Z et al. Cancer Med, December 2023 (epub ahead of print)
    – open access publication
     
    November 2023
    European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
    Cross NCP et al. Leukemia, November 2023
    – open access publication
    Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
    Huuhtanen J et al. Leukemia, November 2023
    (epub ahead of print)
    – open access publication 
    Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study
    Zambrotta GPM et al. Am J Hematol, November 2023
    – open access publication
    Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
    Shin JE et al. Mol Cancer, November 2023
    – open access publication
    Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia:
    Results from the phase 4 BYOND study

    Rosti G et al. Leukemia, November 2023
    (epub ahead of print)
    – open access publication
    Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
    Häselbarth L et al. BMC Cancer, November 2023
    – open access publication 
    Survival with chronic myeloid leukemia after failing milestones
    Lauseker M et al. Leukemia, November 2023
    – open access publication
     
    What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?
    Kantarjian HM Leukemia, November 2023
     
    The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib
    Mulas O et al. Ann Hematol, November 2023
     
    Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
    Park H et al. Ther Adv Hematol, November 2023
    – open access publication

    Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients
    Rafiq Mohammed A et al. Gene, November 2023 


    October 2023
    Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review
    Aldapt MB et al. Oncology, October 2023
    (epub ahead of print)
    Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review
    Verhagen NE et al. Pharmaceutics, October 2023
    – open access publication
    Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia:
    a systematic review and network analysis – Review
    Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print)
    Mitochondrial complex I inhibition by homoharringtonine:
    A novel strategy for suppression of chronic myeloid leukemia

    Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print)
    Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
    Larfors G et al. Eur J Haematol, October 2023
    – open access publication
    A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
    Zhang X et al. Cell Mol Biol Lett, October 2023
    – open access publication
    Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
    Khadadah FM et al. Leuk Res, October 2023
    AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells
    Lapa BS et al. Int J Mol, October 2023
    – open access publication
    Revisiting six established practices in the treatment of chronic myeloid leukemia - Review
    Kantarjian HM et al. Lancet Haematol, October 2023
    Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis
    Boucher L et al. Int J Mol, October 2023
    – open access publication 
    Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results
    Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
     
    Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report
    Alshurufa A et al. Case Rep Oncol, October 2023
    – open access publication
     
    Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
    Efficace F et al. Cancer, October 2023
    (epub ahead of print)
     

    Find publications on pediatric CML here
    Find publications on COVID-19 and CML here
    Find CML publications from the emerging regions here

    CML Publications 2014-2023

    Access 2023 CML publications here

    Access 2022 CML publications here

    Access 2021 CML publications here

    Access 2020 CML publications here

    Access 2019 CML publications here

    Access 2018 CML publications here

    Access 2017 CML publications here

    Access 2016 CML publications here

    Access 2015 CML publications here

    Access 2014 CML publications here


    Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!

    Search for more publications on CML at PubMed.gov